Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  

| More

Lupin Q4FY21 Results Review - Positives in the price - HDFC Securities

Posted On: 2021-05-16 06:42:13 (Time Zone: UTC)

Mr. Bansi Desai, CFA, HDFC Securities and Mr. Karan Vora, Institutional Research Analyst, HDFC Securities

Lupin's 4Q sales/EBITDA was ~5%/9% below our estimates, largely on account of subdued US (+4% QoQ, weak flu season offset Albuterol contribution) and weak API business (-22% YoY). EBITDA margin at 18.7% remained flat QoQ. Management guided for double-digit growth in key markets (India and US) in FY22 and EBITDA margin improvement to 21-22% by FY23 (vs. 17.2% in FY21). We continue to remain positive on Lupin's ability to execute and monetise its complex pipeline in the US (inhalers and complex injectables). We factor in ~460bps margin improvement (to 21.8%) and ~40% earnings CAGR over FY21-23e, driven by operating leverage. However, at 31x/23x FY22/23 EPS, the positives appear priced in. We tweak our estimates by -3%/+4% for FY22/23e and revise the TP to INR1,220. Downgrade to ADD.

Soft quarter, lower tax boosted PAT: Revenue declined by 2% to INR37.8bn as healthy growth in India and growth markets (+8% YoY) offset the subdued performance in the US (+4% QoQ) and API business (-22% YoY, lower antibiotic volumes). EBITDA margin at 18.7% remained flat QoQ as savings in staff cost (-98bps QoQ, lower incentives, one off) were offset by higher other expenses (+70bps QoQ) and R&D (+30bps QoQ). Adj. PAT at INR4.6bn (+50% YoY) was boosted by lower tax rate of 10%.

US pipeline provides decent growth visibility: Among the key existing products, Albuterol ramp-up (8%+ Gx share) has been slower than our expectation; however, Lupin continues to aim for 20% market share over the next few quarters. Levothyroxine has seen improvement in market share (~19% vs. 12% in FY20). New product pipeline - gBrovana (FY22), gSpiriva (FY23), gSuprep (FTF, USD200mn, FY23) and possibly gDulera (FY23) - provide strong growth visibility in the near to medium term. We forecast 15% CAGR over FY21-23e, led by ramp-up in existing products, new launches, and monetisation of inhalation pipeline.

Key call takeaways: (a) Guidance: EBITDA margin of ~21-22% by FY23, US - targets USD1bn sales in two years, ETR - ~27-28% in FY22/23; (b) key product updates in EU - gFostair - expect launch in coming months, bEnbrel - ramp-up to be gradual; (c) US pipeline - gBrovana to be launched in CY21, Peg-filgrastim - filed, awaiting FDA inspection, to launch in 15-18 months, gSpiriva - under priority review, expected to be launched in FY23, litigation is ongoing; (d) USFDA inspection - draft guidelines to conduct remote inspection is in place; however, there is no clarity on timelines.

Downgrade to ADD, risks: We tweak our estimates by -3%/+4% for FY22/23e to account for lower US sales and lower tax rate and revise the TP to INR1,220, based on 23x FY23e EPS. At 31x/23x FY22/23 EPS, the positives appear priced in. Downgrade to ADD. Key risks: delay in key approvals, delay in resolution of plants, lower-than-expected margin expansion.

Shares of LUPIN LTD. was last trading in BSE at Rs.1178.8 as compared to the previous close of Rs. 1210.75. The total number of shares traded during the day was 329802 in over 9148 trades.

The stock hit an intraday high of Rs. 1233 and intraday low of 1165.95. The net turnover during the day was Rs. 392282538.

Source: Equity Bulls

Click here to send ur comments or to

Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only., its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.

Other Headlines:

CESC Q4FY21 Results Review Report - Loss decline, strong CF make valuation attractive - HDFC Securities

White Goods & Durables - Analysis of pressure cooker market: TTK Prestige is key beneficiary - ICICI Securities

CESC - Good earnings in a challenging environment - ICICI Securities

Somany Ceramics - Walking the talk - ICICI Securities

DB Corp - Rise in newsprint price adds to risk - ICICI Securities

CEAT - Market share ambitions remain strong - ICICI Securities

Consumer Staples & Discretionary - Worm's world view #32: Conversations with paint dealers regarding price hikes - ICICI Securities

Oil & Gas - Oil, gas & spot LNG surge to bring gains for GAIL & OIL - ICICI Securities

Asset Management Companies - Positive trends to support earnings - ICICI Securities

Q4FY21 Result Update - Lemon Tree Hotels - ICICI Direct

Q4FY21 Company Update - Globus Spirits - ICICI Direct

Q4FY21 Result Update - DB Corp - ICICI Direct

Q4FY21 Result Update - Somany Ceramics - ICICI Direct

KEC International: Company Update - Building on diversification - HDFC Securities

LIC Housing Finance - Q4 FY21 Result Update - YES Securities

Entertainment Network Ltd - Beating on solutions business - ICICI Securities

Asahi India Glass - Operating leverage, product mix aid margins - ICICI Securities

Whirlpool of India - Market leading revenue growth - ICICI Securities

Lemon Tree Hotels - Wait for recovery gets longer - ICICI Securities

LIC Housing Finance - Stupendous growth momentum; needs to shore up provisioning and capital buffer - ICICI Securities

Quant Pick - Bank of Baroda - ICICI Direct

Company Update - Amara Raja Batteries - Investor Event Outcome - ICICI Direct

Q4FY21 Result Update - Bhel - ICICI Direct

Q4FY21 Company Update - NRB Bearings - ICICI Direct

CESC - Q4FY21 First Cut - ICICI Direct

Q4FY21 Result Update - Entertainment Network India - ICICI Direct

LIC Housing Finance Results Review Report - Balance sheet beefs up; P&L to stay soft - HDFC Securities

Jubilant FoodWorks 4QFY21 Results Review Report - Missing excitement; recovery priced in - HDFC Securities

BFSI Sector Update - MFI Consultation Paper Takeaways - Incrementally positive for NBFC-MFIs - HDFC Securities

Q4FY21 Result Update - JK Cement - ICICI Direct

Q4FY21 Result Update - Minda Industries - ICICI Direct

Stock Tales - Indo Count Industries - ICICI Direct

IPO Review - Krishna Institute of Medical Sciences Ltd - ICICI Direct

Q4FY21 Company Update - Greenply Industries - ICICI Direct

IPO Review - Dodla Dairy Ltd - ICICI Direct

Lemon Tree Hotels - Q4FY21 First Cut - ICICI Direct

Jubilant Foodworks - Q4FY21 investor call takeaways - YES Securities

Greenply Industries Ltd - Q4 FY21 Result Update - YES Securities

Whirlpool of India Ltd - Q4 FY21 Result Update - YES Securities

New India Assurance Report - CoRs disappoint yet again - HDFC Securities

Maintain BUY on Kajaria Ceramics - Performance shines through; outlook bright - HDFC Securities

Retain ADD on Deccan Cement - Volume strong; high other expense dents margin - HDFC Securities

Reiterate ADD on NHPC - Lower generation impacts earnings - HDFC Securities

Maintain BUY on JK Cement - Robust volume and utilisation - HDFC Securities

Maintain BUY on DLF - Gaining traction - HDFC Securities

Maintain BUY on Capacite Infraprojects - Marginal miss - HDFC Securities

DLF Ltd - Q4 FY21 Result Update - YES Securities

Greenply Industries Ltd - Q4FY21 first cut - YES Securities

Coal India - Coal makes a comeback - ICICI Securities

Kajaria Ceramics - Q4FY21 beat largely priced in - ICICI Securities

Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020